Daiichi Sankyo Company, Limited (DSKYF) Stock Price & Analysis
Daiichi Sankyo Company, Limited (DSKYF) — price $17.60 (0.00%), as of the Oct 5, 2026 trading session; market cap $32.0B. Expected results Oct 30, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Daiichi Sankyo Company, Limited · DSKYF · Healthcare · Drug Manufacturers - General
Daiichi Sankyo Company, Limited operates as a global pharmaceutical powerhouse, dedicated to the research, development, manufacturing, and worldwide commercialization of a wide array of medicinal products.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $17.60 | |
| Change on the day | 0.00% | |
| 52-week range | $13.85 – $29.15 | |
| Market capitalisation | $32.0B | |
| Price / earnings (trailing) | 20.59 | |
| Shares traded on the day | 5 | |
| Beta (volatility vs the S&P 500) | 0.12 | |
| Dividends per share (last 12 months) | $0.56 | |
| Dividend yield (last 12 months) | 3.20% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Chronological order, not a duration scale. The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Daiichi Sankyo Company (DSKYF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the DSKYF film — every key number, told as a short cinematic story
~2 min · open the film
What is Daiichi Sankyo Company (DSKYF), and what does it report?
Short answer · as of
Daiichi Sankyo researches, manufactures and commercializes prescription medicines worldwide from its Tokyo base.
Research dated 2026-09-12.
Daiichi Sankyo researches, manufactures and commercializes prescription medicines worldwide from its Tokyo base. Its products span oncology, cardiovascular and neurological care, pain, diabetes, bone health, infections and other conditions, complemented by vaccines, consumer brands, active ingredients and chemical intermediates.
The reported results therefore measure a diversified pharmaceutical group rather than a pure oncology developer. Enhertu is the distinctive growth platform, but consolidated revenue also includes mature medicines and brands such as Lulu, Loxonin S, Transino and Minon; the income statement does not isolate those economics in the figures shown here.
What do the latest results show for Daiichi Sankyo Company (DSKYF)?
Short answer · as of
The most recent reported quarter, Q1 FY2027, carried revenue of $3.61B. Against analyst estimates the company has EPS beat 5 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $3.53B Jul 31, 2026
- Latest report · revenue estimate
- $3.28B Jul 31, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 31, 2026
- Latest report · EPS vs estimate
- Below estimate Jul 31, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 31, 2026 | $3.53B | $3.28B | $0.2319 | $0.2521 |
| May 11, 2026 | $3.71B | $3.74B | $0.1455 | $0.3304 |
| Jan 30, 2026 | $3.56B | $3.51B | $0.2986 | $0.2498 |
| Oct 31, 2025 | $3.39B | $3.35B | $0.1658 | $0.3030 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2027 | $3.61B | $431M | $0.24 (diluted) |
| Q4 FY2026 | $3.76B | $270M | $0.15 (diluted) |
| Q3 FY2026 | $3.54B | $549M | $0.30 (diluted) |
| Q2 FY2026 | $3.22B | $291M | $0.16 (diluted) |
What are the financial strengths and risks for Daiichi Sankyo Company (DSKYF)?
Short answer
The distress and quality screens read Altman Z 2.93 · Piotroski F 6. Trailing ratios: ROE 14.4% · ROA 5.9% · current ratio 2.92 · earnings yield 4.9% · free-cash-flow yield -0.0%.
What should you watch next at Daiichi Sankyo Company (DSKYF)?
Short answer · as of
The next earnings report is expected on Oct 30, 2026.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
What has been published about Daiichi Sankyo Company (DSKYF)?
- New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk
- DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
- Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio
Daiichi Sankyo Company Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What makes Enhertu important to Daiichi Sankyo?
Enhertu places an antibody-drug conjugate at the center of Daiichi Sankyo’s oncology offering. Its commercial contribution sits within a much broader portfolio of prescription medicines, vaccines and consumer products.
Why is Daiichi Sankyo developing Guardant’s companion diagnostic?
The collaboration is intended to identify patients with advanced metastatic non-small cell lung cancer for treatment with Enhertu. That links diagnostic selection directly to the addressable use of the therapy.
How do Lulu and Loxonin S change Daiichi Sankyo’s business mix?
Lulu and Loxonin S give Daiichi Sankyo consumer health exposure alongside prescription medicines. Transino, Minon and oral-care brands broaden that presence further, making the group more diversified than an oncology-only developer.
What is the DSKYF stock price today?
The last price recorded on this page for Daiichi Sankyo Company, Limited (DSKYF) is $17.60, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does DSKYF pay a dividend?
Yes. Daiichi Sankyo Company, Limited (DSKYF) shows a trailing 12-month dividend yield of 3.20%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (39 figures)
The 39 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 30 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $17.60 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T13:44:58.696Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $32.0B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T13:44:56.368Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Oct 30, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Daiichi Sankyo Company, Limited operates as a global pharmaceutical powerhouse, dedicated to the research, development, manufacturing, and worldwide commercialization of a wide array of medicinal products. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 20.59 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 5 | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.12 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Hiroyuki Okuzawa | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 20,171 | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Daiichi Sankyo Building A/B, Tokyo, TY, 103-8426, JP | FMP | Financial Modeling Prep (FMP) company profile | |
fin.q_revenue | Revenue, Q1 FY2027 | $3.61B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-07-31.revenue_actual | Revenue · reported — report date 2026-07-31 | $3.53B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-31.revenue_estimated | Revenue · estimate — report date 2026-07-31 | $3.28B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-31.eps_actual | EPS · reported — report date 2026-07-31 | $0.2319 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-31.eps_estimated | EPS · estimate — report date 2026-07-31 | $0.2521 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.revenue_actual | Revenue · reported — report date 2026-05-11 | $3.71B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.revenue_estimated | Revenue · estimate — report date 2026-05-11 | $3.74B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.eps_actual | EPS · reported — report date 2026-05-11 | $0.1455 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.eps_estimated | EPS · estimate — report date 2026-05-11 | $0.3304 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-30.revenue_actual | Revenue · reported — report date 2026-01-30 | $3.56B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-30.revenue_estimated | Revenue · estimate — report date 2026-01-30 | $3.51B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-30.eps_actual | EPS · reported — report date 2026-01-30 | $0.2986 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-30.eps_estimated | EPS · estimate — report date 2026-01-30 | $0.2498 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-31.revenue_actual | Revenue · reported — report date 2025-10-31 | $3.39B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-31.revenue_estimated | Revenue · estimate — report date 2025-10-31 | $3.35B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-31.eps_actual | EPS · reported — report date 2025-10-31 | $0.1658 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-31.eps_estimated | EPS · estimate — report date 2025-10-31 | $0.3030 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q1 FY2027 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $13.85 – $29.15 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-04 | |
fin.scores | Distress and quality screens | Altman Z 2.93 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 14.4% · ROA 5.9% · current ratio 2.92 · earnings yield 4.9% · free-cash-flow yield -0.0% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.56 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 3.20% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-31.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($3.53B) with the recorded estimate ($3.28B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-31.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.2319) with the recorded estimate ($0.2521) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-07-31. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-31.revenue_actual,earn.history.depth.2026-07-31.revenue_estimated,earn.history.depth.2026-07-31.revenue_actual.comparison,earn.history.depth.2026-07-31.eps_actual.comparison,earn.history.depth.2026-07-31.eps_actual,earn.history.depth.2026-07-31.eps_estimated,earn.history.depth.2026-05-11.revenue_actual,earn.history.depth.2026-05-11.revenue_estimated,earn.history.depth.2026-05-11.eps_actual,earn.history.depth.2026-05-11.eps_estimated,earn.history.depth.2026-01-30.revenue_actual,earn.history.depth.2026-01-30.revenue_estimated,earn.history.depth.2026-01-30.eps_actual,earn.history.depth.2026-01-30.eps_estimated,earn.history.depth.2025-10-31.revenue_actual,earn.history.depth.2025-10-31.revenue_estimated,earn.history.depth.2025-10-31.eps_actual,earn.history.depth.2025-10-31.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | Daiichi Sankyo Company, Limited | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Ticker / exchange | DSKYF on Other OTC | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Headquarters | Daiichi Sankyo Building A/B, Tokyo, TY, 103-8426, JP | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers - General | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Business description | Daiichi Sankyo Company, Limited operates as a global pharmaceutical powerhouse, dedicated to the research, development, manufacturing, and worldwide commercialization of a wide array of medicinal products. The company boasts an extensive portfolio of therapeutics spanning numerous health conditions. In oncology, its offerings include trastuzumab deruxtecan, an innovative anti-HER2 antibody-drug conjugate for cancer treatment, alongside agents such as gefitinib for malignant tumors, bicalutamide for prostate cancer, and tamoxifen for breast cancer. For chronic diseases, Daiichi Sankyo provides mirogabalin for pain management; treatments for type 2 diabetes mellitus like teneligliptin/canagliflozin and teneligliptin; and medications for hypercholesterolemia, including pravastatin and colesevelam (which also addresses type 2 diabetes). Bone health is supported by denosumab for osteoporosis and related conditions, while anemia is managed with ferric carboxymaltose and iron sucrose injections. Its cardiovascular and neurological solutions include the antiplatelet agent prasugrel, the anticoagulant edoxaban, and the antihypertensive olmesartan; as well as lacosamide for epilepsy and memantine for Alzheimer's disease. Other key prescription products address conditions such as ulcers (esomeprazole), influenza (laninamivir), bacterial infections (levofloxacin), dysuria (silodosin), and general pain and inflammation (loxoprofen). Beyond prescription drugs, Daiichi Sankyo also markets a selection of consumer health items. These comprise the multi-symptom cold remedy Lulu, the antipyretic/anti-inflammatory pain reliever Loxonin S, Transino for skin discoloration like melasma and freckles, Minon skincare products, and the oral hygiene brands Breath Labo and Clean Dental. Furthermore, the company produces various vaccines, including those for influenza (both cell culture-derived and HA types), measles, rubella, and mumps. Its diverse operations extend to veterinary pharmaceuticals, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and chemical intermediates. A significant collaboration involves Guardant Health, with whom Daiichi Sankyo is developing Guardant360 CDx as a companion diagnostic for Enhertu, specifically targeting advanced metastatic non-small cell lung cancer. Established in 1899, this long-standing organization is headquartered in Tokyo, Japan. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Named officers | CEO: Hiroyuki Okuzawa; Officers: Joji Nakayama — Title: Senior Adviser, Pay: $1.00M, Born: 1950; Joseph Kenneth Keller — Title: Head of Oncology Business Unit & Global Oncology Business and Director, Pay: $3.26M, Born: 1963; Hiroyuki Okuzawa — Title: President, Chief Executive Officer & Representative Director, Pay: $989,520, Born: 1962; Stuart Mackey — Title: Global Head of Business Development & Director; Takashi Matsumoto — Title: Sr. Exec Ofcr, Chief Corp Affairs Ofcr, Head of Global Corp Affairs & HR, CHRO & Director, Pay: $436,170, Born: 1964; Tomohiro Kodama — Title: Senior Executive Officer, Head of Global Corporate Planning & Management and CFO; Tetsuya Ohira — Title: Corporate Officer, Head of Business Transformation & CTO; Thierry Gruson — Title: Head of Global Oncology Marketing Titles and pay come from the company's proxy statement as our provider parsed it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) |
Data provided for informational purposes only.